Discovery of a Novel Class of Potent HCV NS4B Inhibitors: SAR Studies on Piperazinone Derivatives
Authors:
- 29 January 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (5) , 2136-2160
Abstract
HTS screening identified compound 2a (piperazinone derivative) as a low micromolar HCV genotype 1 (GT-1) inhibitor. Resistance mapping studies suggested that this piperazinone chemotype targets the HCV nonstructural protein NS4B. Extensive SAR studies were performed around 2a and the amide function and the C-3/C-6 cis stereochemistry of the piperazinone core were essential for HCV activity. A 10-fold increase in GT-1 potency was observed when the chiral phenylcyclopropyl amide side chain of 2a was replaced with p-fluorophenylisoxazole-carbonyl moiety (67). Replacing the C-6 nonpolar hydrophobic moiety of 67 with a phenyl moiety (95) did not diminish the GT-1 potency. A heterocyclic thiophene moiety (103) and an isoxazole moiety (108) were incorporated as isosteric replacements for the C-6 phenyl moiety (95), resulting in significant improvement in GT-1b and 1a potency. However, the piperazonone class of compounds lacks GT-2 activity and, consequently, were not pursued further into development.Keywords
This publication has 34 references indexed in Scilit:
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor DaclatasvirAntimicrobial Agents and Chemotherapy, 2013
- Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infectionsTrends in Pharmacological Sciences, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectivesGut, 2012
- New Merck and Vertex drugs raise standard of care in hepatitis CNature Biotechnology, 2011
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Genome of Human Hepatitis C Virus (HCV): Gene Organization, Sequence Diversity, and VariationMicrobial & Comparative Genomics, 2000